Inhaled corticosteroids reduce asthma-associated airway hyperperfusion through genomic and nongenomic mechanisms.
Inhaled corticosteroids have both genomic and nongenomic actions on the tracheobronchial (airway) vasculature in patients with bronchial asthma. Genomic actions involve the activation or repression of target genes associated with inflammation, and reduce inflammatory hyperperfusion in the airway. In contrast, nongenomic actions are mediated by rapid cellular mechanisms, and induce transient vasoconstriction. This article reviews recent progress on the mechanisms by which inhaled corticosteroids reverse inflammatory blood flow changes in the airway in asthma.
Horvath
Gabor
G
Department of Respiratory Medicine, Semmelweis University School of Medicine, Diosarok 1/C, Budapest 1125, Hungary. ghorvath.mail@gmail.com
Vasas
Szilvia
S
Wanner
Adam
A
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001249:Asthma / Q000235:genetics / Q000503:physiopathology / Q000517:prevention & control*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008954:Models, Biological; D011652:Pulmonary Circulation / Q000187:drug effects
D000305:Adrenal Cortex Hormones